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Dear Editor,  
 
Skin manifestations and respiratory symptoms are 
commonly seen in patients with COVID-19. While 
infection by SARS-CoV-2 and an accompanying 
cytokine storm are proposed to account for respiratory 
symptoms, additional inflammatory mediators 
including histamine may also contribute. In this 
regard, we report the resolution of dyspnea associated 
with urticaria in a 61-year-old female patient acutely 
infected with SARS-CoV-2. The patient’s medical 
history is significant for idiopathic thrombocytopenic 
purpura, hypertension, and gastroesophageal reflux 
disease, and her long-standing medications consisted 
of eltrombopag, hydrochlorothiazide, lisinopril, and 
pantoprazole. The patient had no prior history of 
urticaria, angioedema, or respiratory illness.  Due to 
the severity of her symptoms which developed over 
the course of a few days, the patient was referred to an 
urgent care clinic where intravenous 
methylprednisolone was administered, and tapering 
doses of prednisone were prescribed starting at 50mg. 
Nevertheless, all of her symptoms, particularly the 
urticaria (Figure 1 a,b), continued to worsen, 
prompting her to visit our dermatology clinic where 
she was started on hydroxyzine 25mg q.d. and topical 
triamcinolone acetonide 0.1%. A first-generation 
antihistamine was selected to address both pruritus 
and associated insomnia. Additionally, prednisone 
was discontinued as there was no response to the 
medication. The patient experienced relief of urticaria 
within 4 hours after starting hydroxyzine and reported 
improvement of her dyspnea by the following 
morning. A SARS-CoV-2 test performed at the urgent 
care clinic was positive for the detection of viral 
antigen. The patient’s symptoms completely resolved 
within 5 days after initiating hydroxyzine. The signs 
and symptoms of mast cell activation including 
urticaria and pruritus and response to antihistamines 
suggest that mast cells and their chemical mediators 
play a significant role in the pathophysiology of some 
COVID-19 patients. While case reports have described 
improvement of urticaria and other mast cell-mediated 
symptoms in COVID-19 patients following the 
administration of antihistamines, these cases were co-
founded by the concomitant addition of new 
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Figure 1: Wide-spread urticarial rash involving the chest (a) and arms (b) 
 
Urticaria is a common dermatologic manifestation of 
COVID-19 patients, with an incidence of 19% in a 
prospective study of 375 patients.2 No correlation 
between urticaria and disease severity, or timing of 
onset has been described.3 Possible etiologies of 
urticaria in COVID-19 patients include a reaction to 
viral infection, medications, and stress. The SARS-
CoV-2 virus itself may directly activate mast cells via 
toll-like receptors or signaling molecules such as 
interferon type 1, TNF-α, and/or chemokines.4 It is 
thought that mast cell degranulation may either be 
caused directly by the virus or indirectly through viral 
stimulation of complement fragments C3a and C5a 
activating G-protein-coupled receptors.4 
While cytokine storms, and more recently, bradykinin 
storms, are proposed as mediators in the 
pathophysiology of COVID-19, mast cells and 
histamine may also contribute to the development of 
pulmonary manifestations of COVID-19 patients.5 The 
clinical course of our patient indicates her respiratory 
symptoms appeared solely related to SARS-CoV-2 
induced urticaria.  Release of histamine, 
prostaglandin-D2, and leukotriene-C4 by mast cells 
cause bronchoconstriction.6 Further, the release of 
mast cell cytokines such as IL-1 and IL-6 contribute to 
the development of pulmonary and systemic 
inflammation, as well as urticaria in COVID-19 
patients.3,4,6,7 Preliminary clinical trial reports suggest 
antihistamine treatment mitigates pulmonary 
symptoms in COVID-19 patients. Trials of dual-
histamine receptor blockade with cetirizine-famotidine 
in hospitalized COVID-19 patients with severe 
pulmonary symptoms resulted in marked reductions 
in rates of intubation, mortality, and length of hospital 
stay.8 Additionally, a retrospective study of 1,620 
COVID-19 patients who received the H2 receptor 
antagonist famotidine, showed a statistically 
significant reduction in the rates of intubation and 
death.9 
Based on the observations that urticaria and pruritus 
may accompany pulmonary symptoms, we postulate 
these patients may better respond to antihistamine 
therapy. Therefore, we suggest these dermatologic 
findings are incorporated into the analysis plans of 
clinical studies assessing antihistamines in COVID-19 
patients with pulmonary symptoms. Further, we 
suggest considering antihistamines as a component of 
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